REBYOTA™ Prospective Registry (ROAR)
REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
-
Clinical Trial Information
Trial Contact: Shepherd, Adriane R; Garcia de Djuro, Ginette
Trial Phone: 321 841-2285 ; 321.841.6649
-
IRB No: W23.095.05
Protocol Abbrev: ROAR-000422
Principal Investigator: Udayakumar Navaneethan, MD
Age Group: Adult
Secondary Protocol No: 000422
Treatment: Drug: REBYOTA™
ClinicalTrials.gov ID: NCT05835219
-
Objective
To describe the clinical effectiveness through 8 weeks after treatment with REBYOTA in real-world medical practice
-
Key Eligibility
Inclusion Criteria:
• Signed and dated ICF
• Age ≥ 18 years
• Diagnosis of rCDI as determined by the treating physician.
• Completed antibiotic treatment for the presenting rCDI episode.
• Prescription for REBYOTA to prevent rCDI according to the approved indication.
